Key Takeaways Expert panel developed guidelines for onabotulinumtoxinA use in OAB, emphasizing patient experience and compliance. Recommendations cover patient counseling, pre-procedure urinalysis, ...

Physician Summary: Overcoming Challenges in Accessing New Therapies for NMIBC Access to new therapies for non-muscle invasive bladder cancer (NMIBC) presents several challenges, including cost, ...

Former President Joseph R. Biden’s recent diagnosis of metastatic prostate cancer has put prostate health back into the national spotlight. His courage in sharing his diagnosis, particularly at age 82 ...

Key Takeaways The survey examines urologists' treatment patterns and preferences for non–muscle invasive bladder cancer, providing valuable insights into current practices. Michael S. Cookson, MD, and ...

First-line nivolumab (Opdivo) plus ipilimumab (Yervoy) continued to show improved survival and durable response benefits vs sunitinib (Sutent) in patients with previously untreated advanced renal cell ...

Key Takeaways The PIVOT-PO trial was stopped early after meeting its primary end point of noninferiority to imipenem-cilastatin in treating cUTI. No new safety concerns were identified, with diarrhea ...

Key Takeaways The FDA will evaluate talazoparib and enzalutamide for mCRPC patients unselected for HRR gene alterations, expanding beyond HRR-positive cases. TALAPRO-2 trial data showed significant ...

Key Takeaways UGN-102's NDA is supported by the phase 3 ENVISION trial, showing a 79.6% complete response rate at 3 months for LG-IR-NMIBC patients. The FDA is evaluating if the observed duration of ...

In 2025, cytoreductive nephrectomy (CN) remains an integral part of the multidisciplinary management of metastatic renal cell carcinoma (mRCC). Rapid advances in systemic therapies—particularly immune ...

Significant disparities in Altmetric Attention Scores and citation rates between women and men first/last authors in oncology were reported in a recent study in JCO Oncology Practice. 1 In a recent ...

A recent study examined the relationship between randomized controlled trials and real-world efficacy of prostate cancer treatments. 1 Investigators found that benefits of treatments that are observed ...

The study was assessing the safety and efficacy of adding capivasertib (Truqap) to docetaxel and androgen deprivation therapy (ADT) for the treatment of patients with metastatic castration-resistant ...